Skip to main content
TIANYU BIO-TECHNOLOGY CO.,LTD. logo

TIANYU BIO-TECHNOLOGY CO.,LTD. — Investor Relations & Filings

Ticker · 603717 ISIN · CNE1000030W1 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,621 across all filing types
Latest filing 2025-04-15 Audit Report / Informat…
Country CN China
Listing Shanghai Stock Exchange 603717

About TIANYU BIO-TECHNOLOGY CO.,LTD.

https://www.tianyubiotech.com/

TIANYU BIO-TECHNOLOGY CO.,LTD. specializes in the research, development, and large-scale production of active pharmaceutical ingredients (APIs) and advanced pharmaceutical intermediates. The company focuses on therapeutic areas such as cardiovascular health, diabetes management, and anti-viral treatments. Its core product portfolio includes various sartan-based intermediates and other complex organic synthesis products. TIANYU BIO-TECHNOLOGY emphasizes rigorous quality management systems and adheres to international regulatory standards to ensure product safety and efficacy. By leveraging advanced chemical synthesis technologies and a robust R&D infrastructure, the company provides customized manufacturing solutions and high-quality chemical components to global pharmaceutical partners. Its operations are characterized by a commitment to technical innovation and process optimization in the synthesis of complex molecules.

Recent filings

Filing Released Lang Actions
关于2025年度续聘会计师事务所的公告
Audit Report / Information Classification · 95% confidence The document is an announcement regarding the company's plan to reappoint an accounting firm for auditing services for the fiscal year 2025. It details the accounting firm's background, personnel, business scale, integrity record, and audit fee arrangements. It also describes the internal approval process by the audit committee and board of directors. The document does not contain actual financial statements or audit results but is a formal announcement of the intention to appoint the auditor, pending shareholder approval. The document length is 2603 characters, which is relatively short and consistent with an announcement rather than a full audit report. Therefore, this document fits best as an Audit Report / Information announcement (AR) because it relates to audit matters but is not a full annual report or audit report itself. However, since it is primarily an announcement of auditor appointment and related information, it is more precisely an Audit Report / Information (AR) type rather than a full Annual Report (10-K) or Regulatory Filing (RNS). FY 2025
2025-04-15 Chinese
关于天域生物科技股份有限公司2024年度募集资金存放与实际使用情况的专项鉴证报告
Regulatory Filings
2025-04-15 Chinese
关于青海聚之源新材料有限公司三年业绩承诺实现情况的公告
Regulatory Filings Classification · 95% confidence The document is an announcement by Tianyu Biological Technology Co., Ltd. regarding the performance commitment realization of Qinghai Juzhiyuan New Materials Co., Ltd. over a three-year period. It details the investment, the performance commitment, the failure to meet the commitment, and the compensation arrangements. The document includes specific financial figures and contractual obligations but does not contain full financial statements or comprehensive financial analysis. It is a disclosure related to a specific investment and performance guarantee, typical of a regulatory announcement about a material event or update rather than a full financial report or earnings release. The document length is 2196 characters, which is relatively short and focused on a specific event. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-04-15 Chinese
关于未弥补亏损达到实收股本总额三分之一的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement by the company's board regarding the company's accumulated losses exceeding one-third of its paid-in capital, referencing the audited financial statements for the year ended December 31, 2024. It discusses the reasons for the losses and outlines measures to address the situation. The document is a formal disclosure about a significant financial condition that requires shareholder approval at the upcoming annual general meeting. It is not the full annual report or audit report itself, nor is it a certification or a brief notice. Given the content and context, this is a regulatory announcement about a financial condition requiring shareholder attention, fitting best under Regulatory Filings (RNS). The document length is short (1702 characters), and it is not a report publication announcement or a certification letter. Therefore, the classification is Regulatory Filings (RNS).
2025-04-15 Chinese
2024年度独立董事述职报告（梅婷）
Governance Information Classification · 95% confidence The document is titled as an "Independent Director's Annual Report" for the year 2024 by an independent director of the company. It details the director's background, attendance at board and committee meetings, exercise of duties, communication with auditors, oversight of internal controls, and other governance-related activities. The content focuses on the director's role, governance, compliance with laws and regulations, and protection of shareholder interests. It does not contain financial statements or financial performance data, nor is it a general annual report or audit report. It is a governance-related report specifically about the independent director's duties and activities over the year. Therefore, the document fits best under the category of Governance Information (CGR). The document length is 4153 characters, which is sufficient for a detailed governance report but not a full financial report. No indication of it being a report publication announcement or regulatory filing. Hence, the classification is CGR with high confidence.
2025-04-15 Chinese
关于向控股股东借款暨关联交易的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding a related party transaction where the company plans to borrow funds from its controlling shareholders. It details the terms of the loan, the parties involved, the approval process including board and independent director opinions, and the need for shareholder approval. The document is relatively short (2495 characters) and serves as a formal disclosure of a financing-related transaction rather than a full financial report or detailed financing update. It does not contain financial statements or comprehensive financial data but focuses on the announcement of a capital-related transaction (borrowing from controlling shareholders). Therefore, it fits best under the category of Capital/Financing Update (CAP).
2025-04-15 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.